OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (OTCBB: TBIO) today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.
“We delivered a very strong third quarter with total revenue reaching $8.3 million. This represents growth of 87 percent above the same quarter in 2010 and our third consecutive quarter with increasing sales this year. We think these are great results, and they are due to revenue increases across all three of our operating business units: representing the successful integration of the FAMILION cardiac genetic testing franchise into our reference lab business, strong instrument sales, and increasing demand for our advanced and highly sensitive mutation detection technologies, which are driving increases in our pharmacogenomics business,” said Craig Tuttle, President and Chief Executive Officer.
